A Dose-escalation Study of AND017 in Healthy Subjects

Inclusion Criteria: 1. BMI within 18.0-30.0 kg/m2 (inclusive) 2. Blood Pressure (BP) and 12-lead electrocardiogram (ECG) showing no clinically significant abnormalities during screening; 3. No clinically significant abnormal values in physical examination, clinical laboratory tests, liver function or kidney function; Exclusion Criteria: 1. Current or chronic history of liver disease or known hepatic or biliary abnormalities, including but not limited to ALT, alkaline phosphatase and bilirubin \>1.5xULN (isolated bilirubin\>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%); 2. Subjects with Hb: male \<120 g/L or \>160 g/L, female \<110 g/L or \>150 g/L; 3. Subjects with any abnormalities of hematology during screening: Mean corpuscular volume (MCV), platelet count, serum iron, ferritin; 4. Subjects with a history of medical treatment or disease likely to increase the risk of bleeding or disturbance of blood coagulation; 5. History of deep vein thrombosis, stoke, transient ischemic attack, pulmonary embolism or other thrombosis-related condition within the last five years; 6. History of myocardial infarction, heart failure or acute coronary syndrome; 7. Evidence of active peptic, duodenal or esophageal ulcer disease at screening; 8. History of pulmonary artery hypertension; 9. History of sensitivity to heparin or heparin-induced thrombocytopenia; 10. Subjects with major illness or surgery within past 3 months prior to screening, or planned surgery during study; 11. Known or suspected history of drug abuse within the past 5 years or presence of drug abuse within 3 months before study; 12. Donated blood \>400 mL or significant blood loss equivalent to 400 mL or received blood transfusion within 3months of screening; or donated blood \>200 mL or significant blood loss equivalent to 200 mL within 1 month prior to screening. 13. Participation in any clinical study with an investigational drug, biologic or device within 4 weeks or 5 times the half-life of the specific drug/biologics (whichever is longer), prior to dosing;